1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. Ribosomal S6 Kinase (RSK)
  4. Ribosomal S6 Kinase (RSK) Isoform

Ribosomal S6 Kinase (RSK)

 

Ribosomal S6 Kinase (RSK) Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-N0418
    Quercitrin
    Inhibitor 99.80%
    Quercitrin (Quercetin 3-rhamnoside) is a bioflavonoid compound with potential anti-inflammation, antioxidative and neuroprotective effect. Quercitrin induces apoptosis of colon cancer cells. Quercitrin can be used for the research of cardiovascular and neurological disease research.
  • HY-136848
    SM1-71
    Inhibitor
    SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.
  • HY-19712
    LJH685
    Inhibitor 99.99%
    LJH685 is a potent, ATP-competitive and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC50s of 6, 5, 4 nM, respectively.
  • HY-52101A
    FMK
    Inhibitor 99.45%
    FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.
  • HY-52101
    CMK
    Inhibitor 99.80%
    CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.
  • HY-16104
    BIX 02565
    Inhibitor 99.30%
    BIX 02565 is a potent ribosomal S6 kinase 2 (RSK2) inhibitor with IC50 of 1.1 nM.
  • HY-152944
    S6K1-IN-DG2
    Inhibitor 99.70%
    S6K1-IN-DG2 (Compound 66) is a p70S6K inhibitor (IC50: < 100 nM).
  • HY-N2357
    Eudesmin
    Inhibitor 99.19%
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
  • HY-112400
    Bisindolylmaleimide V
    Inhibitor
    Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC50 value over 100 µM. Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 of 8 µM.
  • HY-P3814
    S6 Kinase Substrate Peptide 32
    S6 Kinase Substrate Peptide 32 is a substrate of Ribosomal S6 Kinase (RSK). S6 Kinase Substrate Peptide 32 can be used to measure the activity of RSKs which phosphorylate ribosomal protein S6.
  • HY-144434
    RSK-IN-1
    Inhibitor
    RSK-IN-1 (compound 7d) is a RSK inhibitor that inhibits the YB-1 phosphorylation. RSK-IN-1 has anti-tumor effects.
  • HY-18507A
    AD57 hydrochloride
    Inhibitor
    AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src.